The Genetics of Longevity: What Actually Replicates

Exceptional longevity runs partly in the genes, but the solid signals are few, and most don't translate into anything you can buy or do.

FOXO3A is the most reproducibly longevity-associated human gene after APOE. The rs2802292 G allele was tied to exceptional longevity in Japanese-American men (OR 2.75 for minor-allele homozygotes) [1], and replicated across German [2], Italian [3], Danish [4], and Chinese [5] cohorts, with a pooled GWAS confirming only APOE and FOXO3 survive genome-wide (OR ~1.17) [6]. The longevity allele is functional, it creates a heat-shock-factor binding site that raises FOXO3 expression under stress [7].

The gene sits on the insulin/IGF-1 (IIS) axis, the most conserved aging pathway known. Humans with lifelong growth-hormone-receptor loss of function (Laron syndrome) develop no cancer and no diabetes over 17 years [8]; a GH-receptor exon-3 deletion tracks with ~10 extra years of life [9]; and partial IGF-1-receptor loss-of-function mutations are over-represented in centenarians [10]. IGF-1 itself follows a U-shaped mortality curve, both low and high are harmful [11]. Barzilai argues this U-curve is female-specific and that centenarians carry a "portfolio" of protective variants offsetting ordinary disease risk [12].

APOE is the other major axis, and it cuts both ways. APOE4 raises Alzheimer's risk dose-dependently (ε3/ε4 OR ~3.2; ε4/ε4 OR ~14.9) [13, 14], and ε4/ε4 homozygosity now looks like a near-fully-penetrant genetic form of the disease, with biomarkers abnormal from age ~55 [15]. The ε2 allele does the opposite, ~40% lower AD odds [13], ~13% lower coronary risk in the common ε2/ε3 state [16], and better survival even after adjusting for Alzheimer's [17].

PCSK9 is the cleanest "genetics → drug" success story in the vertical. Gain-of-function mutations cause familial hypercholesterolemia [18]; loss-of-function mutations lower lifelong LDL and cut coronary disease up to ~88% [19]; and two outcome trials confirmed that drugging the target works (evolocumab MACE HR 0.85 [20]; alirocumab HR 0.85 [21]).

But "longevity gene" rarely means "actionable." The cautionary case is CETP: a variant is the single strongest longevity signal in the Ashkenazi centenarian cohort [22], yet three large CETP-inhibitor trials failed, torcetrapib caused harm [23], dalcetrapib [24] and evacetrapib [25] were flatly null despite huge HDL increases. Raising HDL pharmacologically does not reproduce the genetics.

References

1. Willcox BJ et al. 2008 (PNAS) — FOXO3A rs2802292 G allele; OR=2.75 for longevity in Japanese-American men; IIS pathway; replicated across multiple… · PubMed 18765803
2. Flachsbart F, Nebel A et al. 2009 (PNAS) — FOXO3A rs2802292 G allele; German centenarians/nonagenarians (n=1,762); OR ~1.26; first European… · PubMed 19196970
3. Anselmi CV, Puca AA et al. 2009 (Rejuvenation Res) — FOXO3A Italian replication; Southern Italian centenarians; rs2802288 OR=1.51 (1.15–1.98),… · PubMed 19415983
4. Soerensen M et al. 2010 (Aging Cell) — Danish 1905 birth cohort; n=1,089 oldest-old (143 centenarians) + 736 middle-aged controls; 15 FOXO3A… · PubMed 20849522
5. Li Y, Wang WJ, Cao H et al. 2009 (Human Mol Genet) — Han Chinese centenarians; discovery n=761 centenarians+1,056 controls; independent geographic… · PubMed 19793722
6. Broer 2015, J Gerontol A — CHARGE GWAS; only APOE+FOXO3 replicate · PubMed 25199915
7. Grossi 2018, NAR — rs2802292→HSF1 functional FOXO3 mechanism · PubMed 29733381
8. Guevara-Aguirre J, Longo VD et al. 2011 (Sci Transl Med) — 99 Laron syndrome subjects (Ecuador) vs 1,266 relatives; 17-year follow-up; 0 cancer… · PubMed 21325617
9. Ben-Avraham D, Barzilai N et al. 2017 (Science Advances) — GHRd3 longevity; 4 cohorts n=841; d3/d3 homozygosity increases linearly with age… · PubMed 28630896
10. Suh 2008, PNAS — IGF1R mutations in Ashkenazi centenarians · PubMed 18316725
11. Rahmani et al. 2022 (Aging Cell) — Longo meta-analysis; 19 studies, 30,876 subjects; U-shaped IGF-1/mortality; optimal ~120–160 ng/mL ≈ ~50–80… · PubMed 35048526
12. Attia ep204 — Barzilai: metformin + centenarian genetics
13. Farrer LA, Cupples LA, Haines JL et al. 1997 (JAMA) — 40-consortium meta-analysis; n=5,930 AD + 8,607 controls; ε2/ε3 OR 0.6 (0.5–0.8) for AD vs… · PubMed 9343467
14. Corder 1993, Science — APOE4 gene dose & AD risk (dose-dependent) · PubMed 8346443
15. Fortea 2024, Nat Med — APOE4/4 as a distinct genetic form of AD · PubMed 38710950
16. Kuo CL et al. 2020 (Aging Albany NY) — UK Biobank PheWAS; n=379,703 European-descent, 9.4y follow-up; ε2/ε3: LDL −0.43 SD, CAD OR 0.87 (0.83–0.90),… · PubMed 32511104
17. Shinohara M et al. 2020 (eLife) — NACC (n=24,661; 5,413 deaths) + apoE-TR mouse survival cohort (n=118); APOE2 survival advantage persists after… · PubMed 33074098
18. Abifadel 2003, Nat Genet — PCSK9 gain-of-function FH (discovery) · PubMed 12730697
19. Cohen JC, Boerwinkle E, Mosley TH Jr, Hobbs HH. 2006 (NEJM) — ARIC study; 15yr prospective; n=3,363 Black + 9,524 White subjects; PCSK9 LOF… · PubMed 16554528
20. Sabatine MS et al. (FOURIER Steering Committee). 2017 (NEJM) — Phase 3 RCT; n=27,564; median 2.2yr; statin-background secondary-prevention… · PubMed 28304224
21. Schwartz 2018, NEJM — ODYSSEY OUTCOMES alirocumab (MACE HR 0.85) · PubMed 30403574
22. Barzilai N et al. 2003 (JAMA) — CETP I405V variant in ~20% centenarians vs ~3% controls; larger HDL/LDL particles; Ashkenazi Jewish cohort · PubMed 14559957
23. Barter PJ et al. (ILLUMINATE Investigators). 2007 (NEJM) — Torcetrapib in 15,067 high-risk patients on statin background; HDL +72%, LDL −25%;… · PubMed 17984165
24. Schwartz GG et al. (dal-OUTCOMES Investigators). 2012 (NEJM) — Dalcetrapib in 15,871 post-ACS patients; HDL +31%, LDL minimal change; primary MACE:… · PubMed 23126252
25. Lincoff AM et al. (ACCELERATE Investigators). 2017 (NEJM) — Evacetrapib in 12,092 high-risk patients; HDL +134%, LDL −37% — largest biomarker… · PubMed 28514624